AAIC 2025 Abstract
Multiple‐Dose Results from an Ongoing Phase 1 Study of Mivelsiran, an Investigational RNA Interference Therapeutic Targeting Amyloid‐Beta Precursor Protein for Alzheimer’s Disease
Trial in peopleInterventions
Abstract
Background: Single doses of mivelsiran, an investigational RNA interference (RNAi) therapeutic, have demonstrated robust amyloid‐beta precursor protein (APP) lowering in the CNS.
